Funding for this research was provided by:
National Medical Research Council (NMRC/CSA-SI/0004/2015, NMRC/CG/M005/2017_NCIS, NMRC/CG/012/2013)
Received: 29 July 2020
Accepted: 4 November 2020
First Online: 17 November 2020
Ethics approval and consent to participate
: The study was approved by the institutional review board at each participating centre (Domain Specific Research Board approved on 23rd April 2013 for the Singapore site [Reference number 2013/00170] and Medical Ethics Committee University Malaya Medical Centre on 19th June 2013 for the Malaysia site [Protocol number BR01/08/13]) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.Written informed consent was obtained from all individual participants included in the study.
: Not applicable.
: RAS: Honoraria: Astra Zeneca, BMS, Boehringer Ingelheim, Eli-Lilly, Merck, Novartis, Pfizer, Roche and Taiho; Research grant: Astra-Zeneca.RS: Advisory board: BMS, Merck, Eisai, Bayer, Taiho; honoraria for talks: MSD, Eli Lilly, BMS, Roche, Taiho; Travel funding: Roche, Astra Zeneca, Taiho, Eisai; Research funding: Paxman Coolers, MSD.These are outside the submitted work.SGWO: Honoraria: Pfizer, Astra Zeneca, Novartis, Eli Lily.BCT: Honoraria for workshops: Boehringer Ingelheim; Royalty: Wiley-Blackwell.SCL: Advisory board: Roche, MSD, Astra Zeneca, Pfizer, Novartis, Eli Lilly, ACT Genomics, Eisai; honoraria for talks: Astra Zeneca, Pfizer, Novartis, ACT Genomics, Eisai; Research Funding: Taiho, Eisai, Pfizer, ACT Genomics, ASLAN Pharmaceuticals Ltd.; Travel funding for conferences: Amgen, Pfizer.The other authors declare that they have no competing interests.